Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas

Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase (FT). FT catalyzes the post-translational attachment of farnesyl groups to signaling proteins that are required for localization to cell membranes. Although all RAS isoforms are FT substrates, only HRAS is exclusively depen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Gilardi, Mara, Wang, Zhiyong, Proietto, Marco, Chillà, Anastasia, Calleja-Valera, Juan Luis, Goto, Yusuke, Vanoni, Marco, Janes, Matthew R., Mikulski, Zbigniew, Gualberto, Antonio, Molinolo, Alfredo A., Ferrara, Napoleone, Gutkind, J. Silvio, Burrows, Francis
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7484242/
https://ncbi.nlm.nih.gov/pubmed/32727882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-0958
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados